Staff Contact: Keri Barclay or Kara Amann-Kale
This week, the U.S. Department of Health and Human Services announced that the ordering process for monoclonal antibody drugs will transition from the direct ordering process to a state-coordinated distribution system, similar to that used from November 2020 to February 2021. As of yesterday, the following changes have been implemented.
- Administration sites no longer order directly from AmerisourceBergen.
- Weekly distribution amounts for each state/territory will be determined by HHS based on weekly reports of new COVID-19 cases and hospitalizations, in addition to data on inventories and use submitted in HHSProtect.
- State/territorial health departments will determine where product goes in their jurisdictions.
The Missouri Department of Health and Senior Services is working to develop a request process, and MHA will communicate the process as soon as it is available.
HHS is hosting two recurring calls for stakeholders. A stakeholder call, “Weekly Healthcare and Hospital Associations/Organizations Update of COVID-19 Therapeutics from HHS/ASPR,” will be held at 2:15 p.m. on Wednesdays. The call provides an opportunity to receive current information on the allocation, distribution and administration efforts surrounding mAb therapeutics. Additionally, the webinar, “Federal COVID-19 Response: Monoclonal Antibodies 101,” will be held at 11 a.m. on Fridays for new administration sites and health officials.